Journal of Immunology Research / 2019 / Article / Tab 1

Research Article

Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients

Table 1

Baseline characteristics of 220 CHB patients .

Group ()Sex (M/F)Age (years)ALT (U/l)AST (U/l)HBV DNA (lgIU/ml)HBsAg (lgIU/ml)HBeAg(+) ()

T1 (59)38/2137.0 (32.0–42.0)40.0 (26.0–73.0)33.0 (26.0–60.0)5.48 (4.31–7.05)3.64 (3.22–4.12)38
T2 (42)26/1641.5a (37.3–46.8)22.0b (14.5–28.2)24.0e (19.0–30.5)N.A.3.37 (2.92–4.00)18
C1 (78)59/1934.0 (29.0–41.0)53.0c (34.0.0–93.0)42.0f (29.0–65.0)7.11 (5.17–7.95)3.99 (3.34–4.16)54
C2 (41)36/539.0 (33.0–52.5)25.0d (22.0–28.8)25.0g (22.0–28.8)N.A.3.56 (3.10–3.80)19

Notes: M: male; F: female; ALT: alanine aminotransferase; AST: aspartate transaminase; HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e antigen. a, compared with C1; b, compared with T1; c, compared with T1; d, compared with C1; e, compared with T1; f, compared with T1; g, compared with C1.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.